122 results about "Telomerase" patented technology

The invention relates to the technical field of cell engineering, and particularly discloses a construction method and application of a sika deer immortalized renal epithelial cell line, and the construction method comprises the following steps: taking renal epithelial primary cells from healthy sika deer renal cortex tissues to obtain primary renal epithelial cells; treating the primary renal epithelial cells with trypsin to obtain a cell suspension; inoculating the cell suspension into a complete culture medium, and transfecting with lentivirus loaded with SV40 large T antigen genes to obtain transfected cells; 3 [mu] g / mL puromycin is applied to the transfected cells for selective culture, so that non-transfected cells are eliminated, and drug-resistant cells are obtained; carrying out continuous passage on the drug-resistant cells for at least 30 generations to obtain the immortalized renal epithelial cell line of the sika deer; according to the invention, through a specific action mechanism (inhibiting a p53 / pRb pathway and blocking cell cycle exit) of the SV40 large T antigen, a proliferation limit caused by inhibition of telomerase activity of primary cells of the cervidae animals is overcome, and a cell resource library capable of realizing continuous passage is established.

The invention provides a composition for delaying senescence by activating telomerase activity. The composition is prepared from the following raw materials in parts by weight: 12.5 parts of wheat germ concentrated powder, 0.25 to 5 parts of ergothioneine, 0.25 to 5 parts of pyrroloquinoline quinone disodium salt and 0.25 to 5 parts of alpha-ketoglutaric acid. The invention further provides a preparation method and application of the composition for delaying senescence by activating telomerase activity. Through the synergistic effect of the ergothioneine and the pyrroloquinoline quinone disodium salt, the telomerase activity can be activated, the telomerase expression can be improved, the telomere length can be maintained, and the effect of delaying senescence can be achieved, so that the functional metabolism of a human body can be promoted, and the health state of the body can be improved; through the synergistic effect of the wheat germ concentrated powder and alpha-ketoglutaric acid, cell aging can be delayed; through the multi-target synergistic effect of'telomerase activation + mitochondrial repair + autophagy enhancement ', the anti-aging effect is delayed, the metabolic capability is high, the anti-aging effect is good, and safety and high efficiency are achieved; belongs to the technical field of food and health care product processing.

The invention relates to a probiotic preparation containing a BL11 strain and capable of improving obesity-related metabolism and senescence indexes of middle-aged and elderly people and application of the probiotic preparation. The strain in the probiotic preparation is composed of a bifidobacterium longum subsp. Longum BL11 strain and a pediococcus acidilactici PA53 strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of improving obesity-related metabolic indexes, which is specifically embodied in that: the weight increase and body fat rate of mice fed with high fat diet can be reduced; the low-density lipoprotein level, the total cholesterol level and the triglyceride level are reduced, and the high-density lipoprotein level is improved; fasting blood-glucose, glycosylated hemoglobin level and insulin resistance index are reduced; chronic inflammation is relieved; meanwhile, the composition also has excellent performance in the aspect of improving senescence-related indexes, the content of malondialdehyde in serum can be reduced, the activity of superoxide dismutase and glutathione peroxidase can be improved, and the activity of telomerase can be improved.

This document provides methods and materials for manipulating telomere length. For example, this document provides methods and materials for using one or more agents that can manipulate (e.g., increase or decrease) telomere length. In some cases, one or more agents that can increase telomere length can be contacted with a cell to increase telomere length in that cell. For example, one or more agents that can increase telomere length can be administered to a mammal having one or more TBDs to increase telomere length in cells within the mammal (e.g., to treat the mammal). In some cases, one or more agents that can decrease telomere length can be contacted with a cell to decrease telomere length in that cell. For example, one or more agents that can decrease telomere length can be administered to a mammal having a disease or disorder associated with increased telomere synthesis and / or increased telomerase activity to decrease telomere length in cells within the mammal (e.g., to treat the mammal).

The invention provides a DNA library screening method and application of an intracellular mRNA sensor switch. The DNA library screening method comprises the following steps: designing a DNA library containing a switch sequence of a degenerate basic group; preparing a circular expression vector library; preparing a minimum linear expression vector library; performing seamless cloning; carrying out RCA rolling circle amplification; carrying out telomerase digestion; carrying out cell transfection; extracting RNA (Ribonucleic Acid) and carrying out reverse transcription; carrying out library building of next-generation sequencing by taking the cDNA as a template; carrying out next-generation sequencing; analyzing data and comparing to obtain the DNA library of the mRNA sensor switch. According to the DNA library screening method provided by the invention, more sensor switch sequences can be provided for a single site on mRNA in cells, and more selection possibilities are further provided for subsequent targeted therapy.

The present disclosure relates to methods of treating myelodysplastic syndrome. The present disclosure provides methods of treating myelodysplastic syndrome (MDS) in a subject not treated with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The methods comprise administering to the subject an effective amount of a telomerase inhibitor, such as, for example, imestat or imestat sodium. In some cases, a subject being treated is classified as a low or moderate-1IPSS risk MDS subject and / or has an erythropoiesis stimulating agent (ESA) recurrent / refractory MDS.

The invention provides a recombinant herpes simplex virus and a herpes simplex virus modification method. The herpes simplex virus modification method comprises the step of replacing an ICP4 protein coding gene in a herpes simplex virus genome containing an infected cell protein 4 (ICP4) gene with an hTERTp-fluorescent protein expression cassette. The expression cassette comprises an hTERTp promoter and a fluorescent protein coding sequence controlled by the hTERTp promoter, and the transcription direction is opposite to that of an ICP4 promoter in a genome. The hTERTp-fluorescent protein expression cassette in the recombinant virus obtained by the method disclosed by the invention can be normally expressed in response to telomerase activity. Therefore, the recombinant virus is capable of expressing a fluorescent protein, such as mBaoJin, in a cell having human telomerase activity. Cells infected by the virus can be identified through fluorescence signals, and the higher the telomerase activity is, the stronger the fluorescence intensity is. The virus has wide application value in research of tumor action mechanisms and stem cell action mechanisms, health assessment, screening of tumor drugs, research and development of diagnostic reagents and establishment of animal models.

The invention provides a method and a kit for detecting full-length mRNA of a human cell telomerase subunit TERT transcript, and belongs to the technical field of biology. The invention provides a method for detecting human cell telomerase subunit TERT transcript full-length mRNA, a specific reverse transcription primer TERT rt1 is adopted for reverse transcription to obtain cDNA, and if a sixth exon and a seventh exon of the telomerase subunit TERT can be detected in the cDNA, it is judged that a sample to be detected contains the human cell telomerase subunit TERT transcript full-length mRNA. The method disclosed by the invention can be used for distinguishing the full-length mRNA of TERT mRNA and other shear isomer mRNA, and a new technical means is provided for more conveniently, accurately and indirectly evaluating the activity of telomerase in cells.

The present invention discloses a biosensor for detecting telomerase activity, its preparation method and application, which relates to the technical field of biosensors. The preparation method includes the following steps: after the indium tin oxide electrode is cleaned, a Zn-MOFs@Au NPs composite is dropped onto its surface to obtain a Zn-MOFs@Au NPs / ITO electrode; the Zn-MOFs@Au NPs / ITO electrode is immersed in an LH:P double-stranded solution for an incubation reaction to obtain the biosensor; the Zn-MOFs@Au NPs composite is obtained by mixing and reacting gold nanoparticles and zinc-based metal-organic framework materials. The biosensor prepared by the present invention has advantages such as high accuracy, strong sensitivity and good selectivity, and can be applied to the accurate detection of telomerase in cervical cancer cells.

The present disclosure provides transgenic mice for use as mouse models, and methods related thereto. The transgenic mice described herein comprise a humanized mouse telomerase (hmTert) gene included in a background mouse germline that provides shortened telomeres capable of reproducing humans and various human disease states.

Provided are a method for preparing a linear closed DNA and a plasmid for use in the method. The plasmid comprises two editable regions of prokaryotic telomerase target sequences which are connected in tandem in the same direction, and both ends of the editing regions are independently provided with one or more restriction endonuclease digestion sites. The method can yield high-purity LcDNA and can be better applied to clinical research and commercial applications.

The application discloses application of falcarinol-7-methyl ether and derivatives thereof in preparation of medicines and functional foods for delaying aging or immune regulation. In the application, the falcarinol-7-methyl ether and derivatives thereof are derived from falcarinol-7-methyl ether, and can effectively delay replicative senescence of mesenchymal stem cells, inhibit expression of aging-related markers of mouse liver and lung induced by adriamycin, improve grip strength of the mouse, enhance muscle function, and promote proliferation of T cells separated from human peripheral blood mononuclear cells, and have an immune regulation effect. Therefore, the falcarinol-7-methyl ether and derivatives thereof have good effects of improving telomerase activity, anti-aging and immune regulation, and can be developed into anti-aging or immune regulation products.

The invention belongs to the field of food science and engineering, and discloses a preparation method of an active medicinal and edible composite nutrient AMCN with an anti-aging effect, and the preparation method comprises the following steps: putting a ganoderma lucidum monoclonal strain into a liquid culture medium for controllable culture to obtain supernate with beta-glucosidase activity of over 100mU / mL; and adding rhizoma polygonati powder, lucid ganoderma powder and mulberry leaf powder, carrying out enzymatic biotransformation, carrying out lactobacillus plantarum fermentation, adding a freeze-drying protective additive, carrying out freeze-drying, grinding to obtain the active medicinal and edible composite nutrient AMCN, and storing the finished product in a dry and dark place. The active medicinal and edible composite nutrient can be used for preparing anti-aging functional foods or nutritional health-care products. A D-galactose induced zebrafish aging model verifies that the active medicinal and edible composite nutrient prepared by the application plays an anti-aging role by relieving oxidative stress, inhibiting cell aging and maintaining telomere stability, can reduce beta-galactosidase activity and intracellular ROS (reactive oxygen species) level, improves telomerase protein concentration, and has a good anti-aging effect. And the telomere length can be effectively recovered by medium and high concentrations.

The invention belongs to but not limited to the technical field of biomedicine, and discloses a composition with a cell protection effect and application thereof, the composition comprises five monomers of cycloastragenol, resveratrol, ginsenoside, tetrahydrocurcumin and cellulose, and can also comprise a moisturizing composition and a moisturizing composition. The composition provided by the invention can accurately act on vaginal smooth muscle cells and gland cells, and can be used for recovering or improving endocrine balance by improving cell activity, promoting elastin synthesis and repairing cell injury in multiple ways, improving telomerase activity of a reproductive system and regulating immune response, so that the curative effect of the composition is improved. Various injury factors such as exogenous factors, traction of production machinery and age increase are effectively resisted, and the method has wide application prospects in the fields of postpartum reproductive system rehabilitation, maintenance of normal functions of the reproductive system, prevention and improvement of conditions such as vagina relaxation, dryness and poor injury repair and the like, and prevention and treatment of related diseases of the reproductive system and health care.

This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and / or have MDS relapsed / refractory to Erythropoiesis-Stimulating Agent (ESA).

The invention provides a telomerase variant and application of the telomerase variant in anti-aging. Furthermore, compared with the original telomerase, the activity of the telomerase variant is further enhanced, and the improved telomerase variant can more remarkably improve the anti-aging effect. The composition provided by the invention is substantially an anti-aging composition, the composition comprises a high-activity telomerase mutant and a specific auxiliary agent, and the composition has relatively high biological activity, relatively good application prospects and is suitable for marketization.

The application provides a DNA library screening method of intracellular mRNA sensor switch and application. The DNA library screening method comprises the following steps: designing a DNA library containing a switch sequence with a complementary base; preparing a circular expression vector library; preparing a minimized linear expression vector library; seamless cloning; RCA rolling circle amplification; telomerase enzyme cutting; cell transfection; RNA extraction and reverse transcription; library construction by performing second-generation sequencing with the cDNA as a template; second-generation sequencing; data analysis and comparison, and obtaining the DNA library of the mRNA sensor switch. The DNA library screening method provided by the application can provide more sensor switch sequences for a single site on intracellular mRNA, and further provides more selection possibilities for subsequent targeted treatment.

Disclosed are use of a circRNA molecule as a diagnostic marker in a cell senescence diagnosis kit, and use thereof as a treatment target for cell senescence. The present invention finds that circHERC1 is lowly expressed in both cell models of natural senescence and induced senescence. Overexpression of circHERC1 in endothelial cells can improve the proliferation capacity of the endothelial cells, effectively extend the telomere length of the cells, activate telomerase, reduce the β-galactosidase positive rate of the cells, and reduce the expression of all senescence-associated proteins. Introduction of exogenous circHERC1 into mice can effectively delay the senescence of various organs and the shortening of telomeres in aged mice and reduce the β-galactosidase positive rates of various organs of aged mice.

Disclosed herein are dietary supplements, and nutraceutical compositions thereof, comprising a polypeptide having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity to the amino acid sequence set forth in SEQ ID NO 1 and 2; and methods of increasing telomerase activity and extending the length of telomeres using a composition comprising a polypeptide having at least 80%, 85%, 90%, 95%, 98% or 99% sequence identity to the amino acid sequence set forth in SEQ ID NO 1 or 2. Also disclosed is an isolated polypeptide according to SEQ ID NO 2.

The present invention relates to a drug delivery composition comprising a telomerase activator and nanoparticles, and a composition for preventing, improving, or treating hair loss comprising the same. More specifically, the present invention relates to a nanoliposome, nanosilica particle, or nanobubble composition encapsulating drugs such as the plant extract component TA-65 and its derivatives that increase telomerase activity, the telomerase activating compound GPC and its derivatives, and having the efficacy of promoting the regeneration and growth of hair follicles.

This disclosure provides methods of treating a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in a subject in need thereof, wherein the subject treated is classified as having an intermediate-2 or high IPSS risk MDS or AML; or has MDS or AML relapsed, refractory, or intolerant to HMA, venetoclax, or a combination thereof. The method includes administering to the subject an effective amount of a telomerase inhibitor or a pharmaceutically acceptable salt thereof, such as e.g. imetelstat or imetelstat sodium.

The utility model discloses a telomerase activity detection kit, which comprises a kit assembly, a detection module and a detection module, the folding assembly comprises side plates, circular grooves, connecting plates, penetrating grooves, fixing grooves, clamping plates and baffles, the side plates are fixedly connected to the two sides of the upper end of the kit, the circular grooves are formed in the top faces of the side plates and are dotted line grooves, the connecting plates are fixed to the lower portions of one sides of the side plates, and the penetrating grooves are formed in the lower ends of one sides of the connecting plates; the fixing grooves are formed in the middle sections of the two sides of the kit, the clamping plate penetrates through the fixing grooves and the penetrating grooves, and the baffle is fixed to one side of the clamping plate. The kit has the advantages that the circular grooves are vacated, test tubes can be placed in the circular grooves at the moment, so that a placement rack is prevented from being placed in the kit, the kit can contain more reagents or samples by folding the side plates, and laboratory resources can be better managed and utilized.

The present invention is directed to methods and uses of a series of compounds and compositions comprising the same for treating diseases, disorders and / or conditions related to fertility and preserving same and conditions related to same. In some aspects, the compounds and or compositions as herein described promote, improve, recover or restore fertility in a subject in need thereof, including in male and / or female subjects. Such methods / uses include promoting, enhancing or improving fertility-associated cell or tissue yield as part of an in vitro fertilization protocol.

The invention provides a DNA (deoxyribonucleic acid) construct. The construct comprises: 1) a replication start site; 2) screening elements; 3) a target gene; 4) auxiliary elements; and 5) a telomerase recognition site. The constructs can be used to prepare linear endless DNA. The invention also provides a method for producing the endless linear DNA, and an application of the method.

Provided herein are compounds and isolated enantiomers useful for inhibiting telomerase, pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising at least one such compound, isolated enantiomer, or pharmaceutically acceptable salt thereof. Also described is the use of such compounds, isolated enantiomers, or pharmaceutically acceptable salts thereof, and the use of pharmaceutical compositions comprising at least one such compound, isolated enantiomer, or pharmaceutically acceptable salt thereof, in methods of treating disorders or conditions such as cancer, where the cancer may be a hematological malignancy or a solid tumor.

The present invention proposes an innovative imaging strategy, referred to as BioLink imaging ("BioLink" imaging), intended to accurately image the proliferation process of tumor cells by detecting biomarkers closely related to the biological process, such as telomerase (TE) and glutathione (GSH). The invention finds that a significant positive correlation exists between the GSH concentration and the TE activity. Based on the key discovery, the unique sensor is designed and synthesized by the applicant, BioLink imaging is carried out by utilizing biomarkers related to rapid proliferation of tumors and biomarkers generally overexpressed in the tumors, and the stability and specificity of tumor imaging are improved. The research and application of the BioLink imaging not only open up a new view angle for cell biology and pathology research, but also lay a solid foundation for the development of biomedical imaging and disease diagnosis technologies.

This invention discloses a protein-degrading DNA material, its preparation method, and its applications. The protein-degrading DNA material includes a degradation initiation module, a protein targeting module, and a response module. The degradation initiation module is an E3 ubiquitin ligase targeting module, and the response module is a telomerase response module. The preparation method includes the following steps: dissolving the ssDNA strand used in the degradation initiation module in a solvent and annealing it to obtain the degradation initiation module; dissolving the ssDNA strand used in the protein targeting module in a solvent and annealing it to obtain the protein targeting module; dissolving the ssDNA strand used in the response module in a solvent and annealing it to obtain the response module; and mixing the degradation initiation module, the protein targeting module, and the response module to obtain the protein-degrading DNA material. The protein-degrading DNA material of this invention possesses tumor microenvironment triggering characteristics, can precisely target tumor cells, and has a high efficiency in degrading pathogenic proteins.

The invention provides a recombinant herpes simplex virus and a preparation method thereof. The preparation method comprises the step of replacing an original ICP4 coding sequence in a herpes simplex virus genome containing an infected cell protein 4 (ICP4) gene with an hTERTp-ICP4-fluorescent protein expression cassette. The expression cassette comprises an ICP4 coding sequence and a fluorescent protein coding sequence under the control of an hTERTp promoter, and the transcription direction of the expression cassette is opposite to that of an original ICP4 promoter. The recombinant viruses are capable of selectively replicating and indicating telomerase activity in cells having human telomerase activity. Cells infected by the virus can be identified through fluorescence signals, and the higher the telomerase activity is, the stronger the fluorescence intensity is. The virus has wide application value in research of tumor action mechanisms and stem cell action mechanisms, health diagnosis, immune assessment, screening of tumor drugs, research and development of diagnostic reagents and establishment of animal models.

The present disclosure provides a method of inhibiting telomerase activity to reduce human herpesvirus (e.g., HMCV, EBV, HSV-1, and / or HHV-6 / 7 / 8) replication. The method comprises treating cells with a telomerase inhibitor prior to and after HCMV infection. The telomerase inhibitor may be a pharmaceutical inhibitor such as BIBR1532 or MST312, or an siRNA construct targeting the hTERT catalytic subunit of telomerase. Treatment with the telomerase inhibitor results in reduced viral titer, decreased viral gene expression, and diminished viral protein levels across different temporal phases of herpesvirus infection. The method provides a novel approach for inhibiting herpesvirus replication through targeting of host cell telomerase activity.

According to the TelN prokaryotic telomerase variant and the preparation method thereof, compared with wild type TelN prokaryotic telomerase, the TelN prokaryotic telomerase variant has the advantages that the activity is obviously improved, and the TelN prokaryotic telomerase variant has a good industrial application prospect.